Trials / Completed
CompletedNCT02817178
Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer
Prospective Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 258 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Besancon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators recently identified promiscuous HLA-DR-derived epitopes from the human telomerase reverse transcriptase (TERT) called universal cancer peptides (UCP), to study tumor-specific CD4+ T cell responses. The investigators found high frequency of naturally occuring UCP-specific TH1 cells in long term survival of metastatic colorectal cancer (CRC) previously treated by 5 fluoro-uracil -oxaliplatin (Folfox) +/- bevacizumab regiment (Godet et al. OncoImmunology 2012 and unpublished data). Epitopes-CRC02 is a French prospective multicenter study which will evaluate the post chemotherapy and post surgery modulation of host tumor-specific CD4 TH1 cell responses in metastatic colorectal cancer patients and their correlation with progression-free survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Additional biological samples | blood and tumor tissue samples |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2017-06-11
- Completion
- 2020-07-06
- First posted
- 2016-06-29
- Last updated
- 2022-05-11
Locations
9 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02817178. Inclusion in this directory is not an endorsement.